Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
NPJ Microgravity ; 8(1): 18, 2022 Jun 02.
Article in English | MEDLINE | ID: mdl-35654945

ABSTRACT

Alpha(α)Klotho, a soluble transmembrane protein, facilitates calcium-phosphorus homeostasis through feedback between bone and kidney and is a potential systemic biomarker for bone-kidney health during spaceflight. We determined if: (1) plasma αKlotho was reduced after both spaceflight aboard the ISS and hindlimb unloading (HU); and (2) deficiency could be reversed with exercise. Both spaceflight and HU lowered circulating plasma αKlotho: plasma αKlotho recovered with exercise after HU.

2.
Endocrinol Metab Clin North Am ; 48(4): 859-873, 2019 12.
Article in English | MEDLINE | ID: mdl-31655781

ABSTRACT

Untoward side effects of pharmaceuticals can result in considerable morbidity and expense to the health care system. There is likely a sizable fraction of the hypertensive population with disease either induced or exacerbated by polypharmacy. The elevation of blood pressure in drug-induced hypertension occurs through a variety of mechanisms, most notably, sodium and fluid retention, activation of the renin-angiotensin-aldosterone system, alteration of vascular tone, or a combination of these pathways. Recognition of common medications causing drug-induced hypertension is important to effectively control blood pressure. The epidemiology, pathophysiology, and management of these agents are discussed.


Subject(s)
Angiogenesis Inhibitors/adverse effects , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Calcineurin Inhibitors/adverse effects , Central Nervous System Stimulants/adverse effects , Contraceptives, Oral, Hormonal/adverse effects , Glucocorticoids/adverse effects , Hematinics/adverse effects , Hypertension/chemically induced , Hypertension/therapy , Polypharmacy , Serotonin and Noradrenaline Reuptake Inhibitors/adverse effects , Substance-Related Disorders/complications , Humans
3.
Clin J Am Soc Nephrol ; 11(2): 262-70, 2016 Feb 05.
Article in English | MEDLINE | ID: mdl-26668025

ABSTRACT

BACKGROUND AND OBJECTIVES: Prior studies have shown that the APOL1 risk alleles are associated with a greater risk of HIV-associated nephropathy and FSGS among blacks who are HIV positive. We sought to determine whether the APOL1 high-risk genotype incrementally improved the prediction of these underlying lesions beyond conventional clinical factors. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In a cross-sectional study, we analyzed data from 203 blacks who are HIV positive, underwent kidney biopsies between 1996 and 2011, and were genotyped for the APOL1 G1 and G2 alleles. Predictive logistic regression models with conventional clinical factors were compared with those that also included APOL1 genotype using receiver-operating curves and bootstrapping analyses with crossvalidation. RESULTS: The addition of APOL1 genotype to HIV-related risk factors for kidney disease in a predictive model improved the prediction of non-HIV-associated nephropathy FSGS, specifically, increasing the c statistic from 0.65 to 0.74 (P=0.04). Although two risk alleles were significantly associated with higher odds of HIV-associated nephropathy, APOL1 genotype did not add incrementally to the prediction of this specific histopathology. CONCLUSIONS: APOL1 genotype may provide additional diagnostic information to traditional clinical variables in predicting underlying FSGS spectrum lesions in blacks who are HIV positive. In contrast, although APOL1 risk genotype predicts HIV-associated nephropathy, it lacked a high c statistic sufficient for discrimination to eliminate the role of kidney biopsy in the clinical care of blacks who are HIV positive with nephrotic proteinuria or unexplained kidney disease.


Subject(s)
AIDS-Associated Nephropathy/genetics , Apolipoproteins/genetics , Black or African American/genetics , Glomerulosclerosis, Focal Segmental/genetics , HIV Infections/genetics , Kidney/pathology , Lipoproteins, HDL/genetics , AIDS-Associated Nephropathy/diagnosis , AIDS-Associated Nephropathy/ethnology , Adult , Apolipoprotein L1 , Biopsy , Chi-Square Distribution , Cross-Sectional Studies , Female , Genetic Predisposition to Disease , Glomerulosclerosis, Focal Segmental/diagnosis , Glomerulosclerosis, Focal Segmental/ethnology , HIV Infections/diagnosis , HIV Infections/ethnology , Humans , Logistic Models , Male , Middle Aged , Multivariate Analysis , Odds Ratio , Phenotype , Predictive Value of Tests , Retrospective Studies , Risk Assessment , Risk Factors
4.
Clin J Am Soc Nephrol ; 8(9): 1524-32, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23685946

ABSTRACT

BACKGROUND AND OBJECTIVES: HIV-associated nephropathy (HIVAN) is well described, but the clinical features of a group of renal pathologies characterized by Ig or immune complex depositions referred to as HIV-associated immune complex kidney disease (HIVICK) have not been well established. The objective of this study is to assess risk factors for HIVICK compared with contemporaneous control participants. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A nested case-control study of 751 HIV-infected patients followed from January 1996 to June 2010 was conducted. Groups were compared using the chi-squared test or rank-sum analysis. Conditional logistic regression was used to estimate odds ratios (ORs) for HIVICK. Incidences of overall ESRD and with/without combined antiretroviral therapy (cART) exposure were calculated. RESULTS: HIVICK patients were predominantly African American (92%). Compared with matched controls, patients with HIVICK were more likely to have HIV RNA >400 copies/ml (OR, 2.5; 95% confidence interval [95% CI], 1.2 to 5.2), diabetes (OR, 2.8; 95% CI, 1.1 to 6.8), and hypertension (OR, 2.3; 95% CI, 1.2 to 4.5). Compared with HIVAN, patients with HIVICK had more antiretroviral therapy exposure, lower HIV viral loads, and higher CD4 and estimated GFR. ESRD was less common in the HIVICK versus the HIVAN group (30% versus 82%; P<0.001), and the use of cART was not associated with ESRD in HIVICK patients (25% versus 26; P=0.39). CONCLUSIONS: HIVICK was predominantly observed in African-American patients and associated with advanced HIV disease. ESRD incidence is lower in HIVICK patients compared with those with HIVAN. Unlike HIVAN, cART use was not associated with the incidence of ESRD in HIVICK.


Subject(s)
AIDS-Associated Nephropathy/virology , Immune Complex Diseases/virology , Kidney Failure, Chronic/virology , AIDS-Associated Nephropathy/complications , AIDS-Associated Nephropathy/drug therapy , AIDS-Associated Nephropathy/physiopathology , Adult , Black or African American , Anti-Retroviral Agents/therapeutic use , CD4 Lymphocyte Count , Case-Control Studies , Diabetes Complications , Disease Progression , Female , Glomerular Filtration Rate , HIV/genetics , Humans , Hypertension/complications , Immune Complex Diseases/complications , Immune Complex Diseases/drug therapy , Immune Complex Diseases/physiopathology , Kidney Diseases/complications , Kidney Diseases/physiopathology , Kidney Diseases/virology , Male , Middle Aged , RNA, Viral/blood , Risk Factors , United States , Viral Load
5.
Kidney Int ; 82(3): 338-43, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22495294

ABSTRACT

Recently, an association was found between nondiabetic kidney disease in African Americans and two independent sequence variants in the APOL1 gene, encoding apolipoprotein L1. In this study we determined the frequency of APOL1 risk variants in patients with biopsy-proven HIV-associated nephropathy (HIVAN) and distinctive pathological characteristics potentially driven by those risk variants. Among 76 patients with HIVAN, 60 were successfully genotyped for APOL1 G1 and G2 polymorphisms. In this cohort, 37 had two risk alleles, 18 were heterozygous, and 5 had neither risk variant. There were no differences in the pathological findings of HIVAN and the number of APOL1 risk alleles. Further, the progression to end-stage kidney disease or death did not differ by the number of risk alleles. Median renal survival was 9.3 months in patients with zero or one risk allele compared to 11.7 months in patients with two APOL1 risk alleles. Thus, our study suggests that although the majority of African-American patients with HIVAN have two APOL1 risk alleles other as yet unknown factors in the host, including genetic risk variants and environmental or viral factors, may influence the development of this disorder in those with zero or one APOL1 risk allele.


Subject(s)
AIDS-Associated Nephropathy/genetics , Apolipoproteins/genetics , Lipoproteins, HDL/genetics , AIDS-Associated Nephropathy/mortality , AIDS-Associated Nephropathy/pathology , Adult , Black or African American/genetics , Apolipoprotein L1 , Cohort Studies , Female , Gene Frequency , Genetic Variation , Humans , Kaplan-Meier Estimate , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/genetics , Kidney Failure, Chronic/mortality , Kidney Failure, Chronic/pathology , Male , Middle Aged , Risk Factors
6.
Clin Vaccine Immunol ; 19(5): 820-2, 2012 May.
Article in English | MEDLINE | ID: mdl-22441395

ABSTRACT

Screening with hepatitis B surface antigen (HBsAg) is highly recommended for at-risk individuals. Mutations in the HBsAg can result in an inability to detect the virus during routine screening. We describe a hemodialysis patient found to have high levels of hepatitis B virus (HBV) DNA and HBV antibody but negative HBsAg on two routine assays.


Subject(s)
DNA, Viral/blood , False Negative Reactions , Hepatitis B Surface Antigens/blood , Hepatitis B virus/isolation & purification , Hepatitis B/diagnosis , Hepatitis B/virology , Renal Dialysis/adverse effects , Female , Hepatitis B Antibodies/blood , Humans , Middle Aged , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...